|
|
|
|
|
|
|
Cell Line Development For Bispecific Antibodies
|
|
|
See how the recently described cell line development paradigm shift, enabled by the Leap-In transposase platform, can extend to the development of bispecific monoclonal antibody-producing cell substrates.
|
|
|
|
|
|
|
Common light chain reengineering is the traditional answer to mispairing in bispecific and multispecific antibodies, but it often delays timelines. Preserving native IgG structure and biophysical attributes may reduce downstream CMC risk and speed cell line development.
|
|
|
|
|
Light chain mispairing remains a persistent risk in bispecific development, and common light chain workarounds cost time and can compromise performance. A scaffold built on engineered constant regions lets discovered sequences be tested as they are.
|
|
|
|
|
|
|
Improve your cell line development and achieve high productivity, rapid timelines, low risk development, and robust genetic stability with an innovative platform.
|
|
|
